HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors)

Therapeutic Areas

NeoplasmsRespiratory DiseasesUrogenital Diseases

Active Indication

Advanced Cervical CarcinomaAdvanced Lung Non-Small Cell CarcinomaMetastatic Solid Tumor+ [2]

Inactive Indication

Gastrointestinal Neoplasms

Originator Organization

Suzhou Alphamab Co., Ltd.

Active Organization

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC26H24FN3O6

InChIKeyPLXLYXLUCNZSAA-QLXKLKPCSA-N

CAS Registry1599440-33-1

Boost your research with our ADC technology data.

view full example data

Sequence Code 18481L

The sequence is quoted from: *****

Sequence Code 315610456H

The sequence is quoted from: *****

Sequence Code 525560003H

The sequence is quoted from: *****

Sequence Code 525560004H

The sequence is quoted from: *****

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Cervical Carcinoma	Phase 2	China	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	11 Mar 2026
Advanced Lung Non-Small Cell Carcinoma	Phase 2	China	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	14 Nov 2025
Gastrointestinal Neoplasms	Phase 2	Australia	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	18 Jan 2024
Metastatic Solid Tumor	Phase 2	Australia	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	18 Jan 2024
Non-Small Cell Lung Cancer	Phase 2	Australia	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	18 Jan 2024
Advanced cancer	Phase 1	China	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	08 Jan 2025
Recurrent Cervical Cancer	IND Approval	China	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	07 Mar 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06226766 (JSKN033-101, SITC2024) Manual	Phase 1/2	Advanced Malignant Solid Neoplasm	10	JSKN033	lvlcjsuupc(wbepbsbsqc) = The most common was mild to moderate injection site reactions (Grade 1–2). iopqdvwdyt (vrwpmocoxa ) View more	Positive	05 Nov 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis